Q3 EPS Estimate for Stoke Therapeutics Increased by Analyst

Key Points

• Wedbush analysts have increased their Q3 2025 EPS estimate for Stoke Therapeutics from $(0.58) to $(0.57) and maintain an "Outperform" rating with a $22.00 price target.
• Stoke Therapeutics reported a Q2 EPS of $(0.40), beating consensus estimates, but their revenue of $13.82 million fell short of expectations of $31.51 million.
• Several analysts have issued ratings, with a majority giving Stoke Therapeutics a "Buy" rating and an average price target of $25.17, indicating strong investor confidence.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities researchers at Wedbush boosted their Q3 2025 earnings per share estimates for Stoke Therapeutics in a research report issued on Wednesday, August 13th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.57) per share for the quarter, up from their prior estimate of ($0.58). Wedbush has a "Outperform" rating and a $22.00 price target on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics' FY2025 earnings at $0.35 EPS, Q1 2026 earnings at ($0.58) EPS, Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.70) EPS, FY2026 earnings at ($2.58) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($2.12) EPS and FY2029 earnings at $0.30 EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The company had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.

A number of other analysts have also recently commented on STOK. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Chardan Capital reiterated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. HC Wainwright cut their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Finally, Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research report on Friday, July 18th. They set a "buy" rating and a $30.00 target price for the company. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $25.17.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $17.17 on Friday. The stock has a market cap of $940.92 million, a PE ratio of 20.20 and a beta of 1.15. Stoke Therapeutics has a one year low of $5.35 and a one year high of $17.61. The stock has a fifty day moving average of $12.41 and a 200 day moving average of $10.11.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the transaction, the insider owned 25,782 shares in the company, valued at approximately $258,593.46. The trade was a 20.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 12,720 shares of company stock valued at $140,095. 9.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE boosted its holdings in shares of Stoke Therapeutics by 2.9% in the 2nd quarter. Bank of America Corp DE now owns 548,090 shares of the company's stock worth $6,221,000 after purchasing an additional 15,206 shares during the period. MPM Bioimpact LLC boosted its holdings in shares of Stoke Therapeutics by 13.8% in the 2nd quarter. MPM Bioimpact LLC now owns 789,698 shares of the company's stock worth $8,963,000 after purchasing an additional 95,710 shares during the period. Jane Street Group LLC boosted its holdings in shares of Stoke Therapeutics by 28.8% in the 2nd quarter. Jane Street Group LLC now owns 34,743 shares of the company's stock worth $394,000 after purchasing an additional 7,765 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Stoke Therapeutics by 121.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,411 shares of the company's stock worth $607,000 after purchasing an additional 29,244 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Stoke Therapeutics by 14.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company's stock worth $171,000 after purchasing an additional 1,862 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.